0001643918-19-000003.txt : 20191107
0001643918-19-000003.hdr.sgml : 20191107
20191107164849
ACCESSION NUMBER: 0001643918-19-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20191107
DATE AS OF CHANGE: 20191107
EFFECTIVENESS DATE: 20191107
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Midatech Pharma Plc
CENTRAL INDEX KEY: 0001643918
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-352895
FILM NUMBER: 191201057
BUSINESS ADDRESS:
STREET 1: ODDFELLOWS HOUSE
STREET 2: 19 NEWPORT ROAD
CITY: CARDIFF
STATE: X0
ZIP: CF24 0AA
BUSINESS PHONE: 44 (0)1235 888300
MAIL ADDRESS:
STREET 1: ODDFELLOWS HOUSE
STREET 2: 19 NEWPORT ROAD
CITY: CARDIFF
STATE: X0
ZIP: CF24 0AA
D
1
primary_doc.xml
X0708
D
LIVE
0001643918
Midatech Pharma Plc
ODDFELLOWS HOUSE
19 NEWPORT ROAD
CARDIFF
X0
UNITED KINGDOM
CF24 0AA
44 1235 888300
UNITED KINGDOM
None
None
Corporation
true
Craig
Cook
Oddfellows House
19 Newport Road
Cardiff
X0
UNITED KINGDOM
CF24 OAA
Executive Officer
Director
Stephen
Stamp
Oddfellows House
19 Newport Road
Cardiff
X0
UNITED KINGDOM
CF24 OAA
Executive Officer
Director
Frederic
Duchesne
Oddfellows House
19 Newport Road
Cardiff
X0
UNITED KINGDOM
CF24 OAA
Director
Huaizheng
Peng
Oddfellows House
19 Newport Road
Cardiff
X0
UNITED KINGDOM
CF24 OAA
Director
Simon
Turton
Oddfellows House
19 Newport Road
Cardiff
X0
UNITED KINGDOM
CF24 OAA
Director
Sijmen
de Vries
Oddfellows House
19 Newport Road
Cardiff
X0
UNITED KINGDOM
CF24 OAA
Director
Rolf
Stahel
Oddfellows House
19 Newport Road
Cardiff
X0
UNITED KINGDOM
CF24 OAA
Director
Biotechnology
Decline to Disclose
- 06b
false
2019-10-22
false
true
true
false
0
H.C. Wainwright & Co., LLC
375
None
None
430 Park Ave
New York
NY
NEW YORK
10022
NY
NEW YORK
false
3000000
3000000
0
The total offering amount includes the concurrent registered offering of American Depositary Shares.
false
1
210000
0
Sales commission relates to the sale of ADSs in the concurrent registered offering. HCW is also entitled to expense reimbursement up to $25,000, a 1% mgmt. fee and warrants to purchase an aggregate of 150,000 ADSs exercisable at $1.25 per ADS for 5 years.
0
false
Midatech Pharma Plc
Stephen Stamp
Stephen Stamp
Chief Financial Officer
2019-11-07